MARCOS
GONZÁLEZ DÍAZ
Investigador en el periodo 1993-2023
Miguel Ángel
Sanz Alonso
Publicaciones en las que colabora con Miguel Ángel Sanz Alonso (29)
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
2021
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
2020
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
2018
-
Focal adhesion genes refine the intermediate-risk cytogenetic classification of acute myeloid leukemia
Cancers, Vol. 10, Núm. 11
2017
-
NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients
Oncotarget, Vol. 8, Núm. 44, pp. 76003-76014
2015
2012
-
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen
Bone Marrow Transplantation, Vol. 47, Núm. 10, pp. 1287-1293
2011
-
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
Blood, Vol. 117, Núm. 6, pp. 1799-1805
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477
2010
-
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
Haematologica, Vol. 95, Núm. 3, pp. 424-431
-
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group
Blood, Vol. 116, Núm. 25, pp. 5650-5659
2009
-
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
Haematologica, Vol. 94, Núm. 9, pp. 1242-1249
-
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
Blood, Vol. 113, Núm. 4, pp. 775-783
2008
-
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
Blood, Vol. 111, Núm. 7, pp. 3395-3402
-
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
Blood, Vol. 112, Núm. 8, pp. 3130-3134
2007
-
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an early intervention
Leukemia, Vol. 21, Núm. 3, pp. 446-452
-
Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia
British Journal of Haematology, Vol. 136, Núm. 4, pp. 590-596
2005
-
Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: A multicenter study by the PETHEMA Group
Journal of Clinical Oncology, Vol. 23, Núm. 30, pp. 7632-7640
2004
-
Quantitative assessment of PML-RARa and BCR-ABL by two real-time PCR instruments: Multiinstitutional laboratory trial
Clinical Chemistry, Vol. 50, Núm. 6, pp. 1088-1092
-
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group
Blood, Vol. 103, Núm. 4, pp. 1237-1243